Symbols / TMDX Stock $63.93 -0.58% TransMedics Group, Inc.

Healthcare • Medical Devices • United States • NGM
TMDX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Medical Devices
CEO Dr. Waleed H. Hassanein M.D.
Exch · Country NGM · United States
Market Cap 2.21B
Enterprise Value 2.61B
Income 171.92M
Sales 635.89M
FCF (ttm) 108.82M
Book/sh 13.81
Cash/sh 13.36
Employees 898
Insider 10d —
IPO May 02, 2019
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 14.63
Forward P/E 17.98
PEG —
P/S 3.47
P/B 4.63
P/C —
EV/EBITDA 20.83
EV/Sales 4.11
Quick Ratio 6.01
Current Ratio 6.74
Debt/Eq 174.78
LT Debt/Eq —
EPS (ttm) 4.37
EPS next Y 3.55
EPS Growth -71.50%
Revenue Growth 21.20%
EPS Gr Q/Q -71.50%
Rev Gr Q/Q —
Earnings (next) 2026-07-30
Earnings (prior) 2026-05-05
ROA 5.20%
ROE 45.22%
ROIC —
Gross Margin 59.09%
Oper. Margin 7.65%
Profit Margin 27.04%
Shs Outstand 34.56M
Shs Float 33.44M
Insider Own 3.29%
Instit Own 113.74%
Short Float 37.55%
Short Ratio 9.27
Short Interest 8.32M
52W High 156.00
vs 52W High -59.02%
52W Low 62.89
vs 52W Low 1.65%
Beta 2.06
Impl. Vol. 3.13%
Rel Volume 1.27
Avg Volume 1.21M
Volume 1.53M
Target (mean) $117.89
Tgt Median $120.00
Tgt Low $85.00
Tgt High $142.00
# Analysts 9
Recom Buy
Prev Close $64.30
Price $63.93
Change -0.58%
About

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$117.89
Mean price target
2. Current target
$63.93
Latest analyst target
3. DCF / Fair value
$56.68
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$63.93
Low
$85.00
High
$142.00
Mean
$117.89

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-06 main Canaccord Genuity Buy → Buy $124
2026-05-06 main TD Cowen Buy → Buy $120
2026-05-06 main Stifel Hold → Hold $85
2026-05-06 main Piper Sandler Overweight → Overweight $120
2026-05-06 main Needham Buy → Buy $142
2026-04-06 main Evercore ISI Group Outperform → Outperform $118
2026-03-09 main Stifel Hold → Hold $130
2026-02-25 main JP Morgan Neutral → Neutral $149
2026-02-25 main Oppenheimer Outperform → Outperform $175
2026-02-25 main Piper Sandler Overweight → Overweight $160
2026-02-25 main Evercore ISI Group Outperform → Outperform $170
2026-02-25 main Needham Buy → Buy $174
2025-12-17 main Canaccord Genuity Buy → Buy $148
2025-12-08 main Needham Buy → Buy $166
2025-12-02 main Morgan Stanley Equal-Weight → Equal-Weight $135
2025-10-30 main Canaccord Genuity Buy → Buy $147
2025-10-30 main Piper Sandler Overweight → Overweight $140
2025-10-23 up Needham Hold → Buy $148
2025-10-14 main Canaccord Genuity Buy → Buy $142
2025-10-13 init Jefferies — → Buy $145
News
RSS: Latest TMDX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-04 WEILL DAVID Director — 3,571 $14.20 $50,708
2026-03-04 HERNANDEZ GERARDO Chief Financial Officer — 7,236 $69.84 $515,001
2026-03-04 WEILL DAVID Director — 3,571 $146.82 $524,294
2026-03-04 HERNANDEZ GERARDO Chief Financial Officer — 7,611 $139.12 $1,117,382
2026-03-04 LOVELL STEPHANIE Director — 1,193 $149.62 $178,497
2026-03-02 CORCORAN NICHOLAS Officer — 2,966 $139.12 $412,630
2026-03-02 RANGANATH ANIL P General Counsel — 864 $139.12 $120,200
2026-02-18 CECERE GIOVANNI Officer — 11,082 $0.00 $0
2025-12-04 HERNANDEZ GERARDO Chief Financial Officer — 920 $139.62 $128,450
2025-12-03 WEILL DAVID Director — 5,000 $14.20 $71,000
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
605.49
+37.13%
441.54
+82.74%
241.62
+158.53%
93.46
Operating Revenue
605.49
+37.19%
441.35
+82.68%
241.60
+162.38%
92.08
Cost Of Revenue
242.69
+35.23%
179.46
+105.03%
87.53
+210.53%
28.19
Reconciled Cost Of Revenue
242.69
+35.23%
179.46
+105.03%
87.53
+210.53%
28.19
Gross Profit
362.81
+38.43%
262.08
+70.08%
154.09
+136.08%
65.27
Operating Expense
254.22
+13.20%
224.59
+22.84%
182.82
+89.04%
96.71
Research And Development
69.06
+23.38%
55.97
-11.54%
63.27
+135.97%
26.81
Selling General And Administration
185.17
+9.82%
168.62
+41.04%
119.55
+71.04%
69.90
Selling And Marketing Expense
4.32
—
—
18.21
General And Administrative Expense
180.85
+7.26%
168.62
+41.04%
119.55
+131.30%
51.69
Salaries And Wages
114.51
+4.60%
109.47
+50.55%
72.72
+84.80%
39.35
Other Gand A
66.35
+12.18%
59.14
+26.27%
46.84
+279.61%
12.34
Total Expenses
496.91
+22.98%
404.04
+49.45%
270.35
+116.46%
124.90
Operating Income
108.58
+189.59%
37.50
+230.53%
-28.73
+8.62%
-31.44
Total Operating Income As Reported
108.58
+189.59%
37.50
+230.53%
-28.73
+8.62%
-31.44
EBITDA
148.49
+112.29%
69.95
+1008.05%
-7.70
+73.40%
-28.96
Normalized EBITDA
148.49
+112.29%
69.95
+1008.05%
-7.70
+73.40%
-28.96
Reconciled Depreciation
27.18
+37.59%
19.76
+141.63%
8.18
+135.11%
3.48
EBIT
121.30
+141.69%
50.19
+416.05%
-15.88
+51.05%
-32.44
Total Unusual Items
—
—
0.30
+115.79%
-1.90
Total Unusual Items Excluding Goodwill
—
—
0.30
+115.79%
-1.90
Special Income Charges
—
—
-27.21
-4435.33%
-0.60
Other Special Charges
—
—
27.21
+4435.33%
0.60
Net Income
190.29
+436.58%
35.46
+241.70%
-25.03
+30.92%
-36.23
Pretax Income
107.52
+200.51%
35.78
+234.15%
-26.67
+26.25%
-36.16
Net Non Operating Interest Income Expense
-13.78
+4.35%
-14.41
-33.53%
-10.79
-189.61%
-3.73
Interest Expense Non Operating
13.78
-4.35%
14.41
+33.53%
10.79
+189.61%
3.73
Net Interest Income
-13.78
+4.35%
-14.41
-33.53%
-10.79
-189.61%
-3.73
Interest Expense
13.78
-4.35%
14.41
+33.53%
10.79
+189.61%
3.73
Interest Income Non Operating
—
—
12.50
+1288.89%
0.90
Interest Income
—
—
12.50
+1288.89%
0.90
Other Income Expense
12.72
+0.22%
12.69
-1.20%
12.85
+1382.14%
-1.00
Other Non Operating Income Expenses
12.72
+0.22%
12.69
-1.20%
12.85
+1382.14%
-1.00
Gain On Sale Of Security
—
—
0.30
+123.08%
-1.30
Tax Provision
-82.77
-26292.72%
0.32
+119.23%
-1.64
-2589.39%
0.07
Tax Rate For Calcs
0.00
+2233.33%
0.00
-85.48%
0.00
-70.48%
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
190.29
+436.58%
35.46
+241.70%
-25.03
+30.92%
-36.23
Net Income From Continuing Operation Net Minority Interest
190.29
+436.58%
35.46
+241.70%
-25.03
+30.92%
-36.23
Net Income From Continuing And Discontinued Operation
190.29
+436.58%
35.46
+241.70%
-25.03
+30.92%
-36.23
Net Income Continuous Operations
190.29
+436.58%
35.46
+241.70%
-25.03
+30.92%
-36.23
Normalized Income
190.29
+436.58%
35.46
+241.70%
-25.03
+30.92%
-36.23
Net Income Common Stockholders
190.29
+436.58%
35.46
+241.70%
-25.03
+30.92%
-36.23
Diluted EPS
4.87
+382.18%
1.01
+231.17%
-0.77
+37.40%
-1.23
Basic EPS
5.60
+423.36%
1.07
+238.96%
-0.77
+37.40%
-1.23
Basic Average Shares
33.99
+2.30%
33.23
+2.19%
32.52
+10.02%
29.56
Diluted Average Shares
40.54
+15.12%
35.22
+8.30%
32.52
+10.02%
29.56
Diluted NI Availto Com Stockholders
190.29
+436.58%
35.46
+241.70%
-25.03
+30.92%
-36.23
Line Item Trend 2023-12-31
Total Assets
706.05
Current Assets
510.65
Cash Cash Equivalents And Short Term Investments
394.81
Cash And Cash Equivalents
394.81
Cash Financial
394.81
Other Short Term Investments
—
Receivables
63.58
Accounts Receivable
63.58
Inventory
44.23
Raw Materials
25.82
Work In Process
3.81
Finished Goods
14.61
Prepaid Assets
—
Other Current Assets
8.03
Total Non Current Assets
195.39
Net PPE
180.49
Gross PPE
201.78
Accumulated Depreciation
-21.29
Properties
0.00
Land And Improvements
—
Machinery Furniture Equipment
152.37
Construction In Progress
6.25
Other Properties
29.81
Leases
13.35
Goodwill And Other Intangible Assets
14.34
Goodwill
11.99
Other Intangible Assets
2.35
Non Current Deferred Assets
—
Non Current Deferred Taxes Assets
—
Other Non Current Assets
0.56
Total Liabilities Net Minority Interest
568.85
Current Liabilities
54.93
Payables And Accrued Expenses
50.94
Payables
12.72
Accounts Payable
12.72
Current Accrued Expenses
38.22
Current Debt And Capital Lease Obligation
2.04
Current Debt
—
Other Current Borrowings
—
Current Capital Lease Obligation
2.04
Current Deferred Liabilities
1.96
Current Deferred Revenue
1.96
Total Non Current Liabilities Net Minority Interest
513.91
Long Term Debt And Capital Lease Obligation
513.91
Long Term Debt
506.20
Long Term Capital Lease Obligation
7.71
Non Current Deferred Liabilities
—
Stockholders Equity
137.20
Common Stock Equity
137.20
Capital Stock
641.11
Common Stock
641.11
Preferred Stock
0.00
Share Issued
32.67
Ordinary Shares Number
32.67
Treasury Shares Number
0.00
Retained Earnings
-503.70
Gains Losses Not Affecting Retained Earnings
-0.20
Other Equity Adjustments
-0.20
Total Equity Gross Minority Interest
137.20
Total Capitalization
643.41
Working Capital
455.72
Invested Capital
643.41
Total Debt
515.95
Net Debt
111.39
Capital Lease Obligations
9.74
Net Tangible Assets
122.86
Tangible Book Value
122.86
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
192.84
+295.14%
48.80
+474.60%
-13.03
+71.57%
-45.82
Cash Flow From Continuing Operating Activities
192.84
+295.14%
48.80
+474.60%
-13.03
+71.57%
-45.82
Net Income From Continuing Operations
190.29
+436.58%
35.46
+241.70%
-25.03
+30.92%
-36.23
Depreciation Amortization Depletion
27.18
+37.59%
19.76
+141.63%
8.18
+135.11%
3.48
Depreciation And Amortization
27.18
+37.59%
19.76
+141.63%
8.18
+135.11%
3.48
Other Non Cash Items
5.21
+11.49%
4.67
-84.61%
30.38
+2470.30%
1.18
Stock Based Compensation
36.86
+10.95%
33.22
+67.87%
19.79
+91.75%
10.32
Deferred Tax
-83.54
0.00
+100.00%
-1.66
0.00
Deferred Income Tax
-83.54
0.00
+100.00%
-1.66
0.00
Operating Gains Losses
-1.54
-326.10%
0.68
+299.42%
-0.34
-118.88%
1.81
Gain Loss On Investment Securities
—
—
—
0.11
Net Foreign Currency Exchange Gain Loss
-1.62
-343.91%
0.67
+294.44%
-0.34
-130.29%
1.13
Gain Loss On Sale Of PPE
0.08
+370.59%
0.02
0.00
0.00
Change In Working Capital
18.38
+140.84%
-45.00
-1.47%
-44.35
-65.73%
-26.76
Change In Receivables
13.95
+140.66%
-34.31
-1.46%
-33.82
-55.99%
-21.68
Changes In Account Receivables
13.95
+140.66%
-34.31
-1.46%
-33.82
-55.99%
-21.68
Change In Inventory
-7.72
+7.63%
-8.35
+70.27%
-28.09
-250.10%
-8.02
Change In Prepaid Assets
-3.76
+39.97%
-6.26
-198.05%
-2.10
-183.34%
2.52
Change In Payables And Accrued Expense
17.68
+170.18%
6.54
-69.15%
21.21
+12598.80%
0.17
Change In Accrued Expense
17.69
+122.90%
7.94
-44.29%
14.25
+314.61%
3.44
Change In Payable
-0.02
+98.64%
-1.40
-120.07%
6.96
+312.75%
-3.27
Change In Account Payable
-0.02
+98.64%
-1.40
-120.07%
6.96
+312.75%
-3.27
Change In Other Working Capital
1.14
+663.55%
-0.20
-344.58%
0.08
—
Change In Other Current Assets
-0.02
+84.56%
-0.15
-175.93%
-0.05
0.00
Change In Other Current Liabilities
-2.90
-27.81%
-2.27
-43.90%
-1.57
-717.25%
0.26
Investing Cash Flow
-59.25
+54.18%
-129.30
+33.33%
-193.95
-455.79%
54.51
Cash Flow From Continuing Investing Activities
-59.25
+54.18%
-129.30
+33.33%
-193.95
-455.79%
54.51
Net PPE Purchase And Sale
-59.25
+54.33%
-129.74
+14.56%
-151.85
-1175.28%
-11.91
Purchase Of PPE
-59.25
+54.33%
-129.74
+14.56%
-151.85
-1175.28%
-11.91
Capital Expenditure
-59.25
+54.33%
-129.74
+27.54%
-179.06
-1403.81%
-11.91
Net Investment Purchase And Sale
—
0.00
0.00
-100.00%
66.42
Purchase Of Investment
—
0.00
0.00
+100.00%
-10.50
Sale Of Investment
—
0.00
0.00
-100.00%
76.92
Net Business Purchase And Sale
0.00
-100.00%
0.44
+102.96%
-14.89
0.00
Purchase Of Business
—
—
-14.89
0.00
Net Intangibles Purchase And Sale
0.00
0.00
+100.00%
-27.21
0.00
Purchase Of Intangibles
0.00
0.00
+100.00%
-27.21
0.00
Financing Cash Flow
16.86
-26.30%
22.87
-94.29%
400.42
+138.45%
167.93
Cash Flow From Continuing Financing Activities
16.86
-26.30%
22.87
-94.29%
400.42
+138.45%
167.93
Net Issuance Payments Of Debt
0.00
0.00
-100.00%
445.38
+1883.08%
22.46
Issuance Of Debt
0.00
0.00
-100.00%
445.38
+661.22%
58.51
Repayment Of Debt
—
0.00
0.00
+100.00%
-36.05
Long Term Debt Issuance
0.00
0.00
-100.00%
445.38
+661.22%
58.51
Long Term Debt Payments
—
0.00
0.00
+100.00%
-36.05
Net Long Term Debt Issuance
0.00
0.00
-100.00%
445.38
+1883.08%
22.46
Net Common Stock Issuance
—
0.00
0.00
-100.00%
139.85
Proceeds From Stock Option Exercised
17.00
-25.70%
22.87
+221.72%
7.11
+26.65%
5.61
Net Other Financing Charges
-0.14
—
-52.07
—
Changes In Cash
150.45
+361.07%
-57.63
-129.79%
193.44
+9.52%
176.62
Effect Of Exchange Rate Changes
1.27
+336.94%
-0.54
-377.72%
0.19
+118.90%
-1.02
Beginning Cash Position
337.15
-14.71%
395.31
+96.01%
201.68
+673.32%
26.08
End Cash Position
488.87
+45.00%
337.15
-14.71%
395.31
+96.01%
201.68
Free Cash Flow
133.59
+265.04%
-80.94
+57.86%
-192.09
-232.77%
-57.72
Interest Paid Supplemental Data
10.70
-5.27%
11.30
+39.66%
8.09
+148.13%
3.26
Amortization Of Securities
—
0.00
0.00
-100.00%
0.38
Common Stock Issuance
—
0.00
0.00
-100.00%
139.85
Issuance Of Capital Stock
—
0.00
0.00
-100.00%
139.85
Sale Of Business
0.00
-100.00%
0.44
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category